Key Highlights

  • MBRX shares traded up 20.19% to $6.37, versus a prior close of $5.30.
  • The CEO Corner update covered the Phase 2/3 MIRACLE trial of Annamycin in relapsed or refractory AML.
  • Part A enrollment is complete, with a full 90-patient readout expected in the first quarter of 2027.
  • Market capitalization is only about $6.49 million.
  • The company says it needs significant additional financing.

A CEO Corner Segment Puts the MIRACLE Trial Back in View

Moleculin Biotech (NASDAQ:MBRX) shares traded up 20.19% to $6.37 after the company released a new CEO Corner segment. In it, CEO Walter Klemp discusses progress in the Phase 2/3 MIRACLE trial of Annamycin with high-dose cytarabine in second-line relapsed or refractory acute myeloid leukemia.

The update covers completed Part A enrollment, encouraging interim efficacy results and the potential for Annamycin to address treatment resistance and the cardiac safety concerns tied to conventional anthracyclines.

Full Part A Data Are Expected in the First Quarter of 2027

Mr. Klemp said the full 90-patient Part A readout is expected in the first quarter of 2027. He also outlined next steps toward the pivotal Part B expansion. Annamycin carries FDA Fast Track and Orphan Drug designations for AML.

The company is also testing Annamycin in soft tissue sarcoma lung metastases. The update contained no new data tables, so the interim comments remain company statements from a limited patient group.

Tiny Market Value and Financing Needs Raise the Stakes

Moleculin has a market capitalization of about $6.49 million, 17 full-time employees and earnings per share of a loss of $15.37. Volume was about 121,740 shares. The company says it will need significant additional financing, for which it has no commitments, to run its trials.

Share counts and prices in small caps like this can move sharply on low volume, and the company has also carried out a reverse stock split.

Funding and the First-Quarter Readout Decide the Next Chapter

Investors will watch for financing news ahead of the Part A data. The results will shape dose selection for Part B and any further discussion with the FDA.